|Cancer||breast cancer,colorectal cancer,esophageal squamous cell cancer,osteosarcoma,|
LncRNA 91H is the antisense of H19. It is expressed in the higher percentage of colorectal cancer (1), breast cancer (2) and osteosarcoma (3). The high expression of 91H is significantly correlated with distant metastasis in colorectal cancer, and also correlated with advanced clinical stage, chemotherapy after surgery, and tumor size in osteosarcoma. There would be an obviously poorer prognosis if 91H expression rose in colorectal cancer and osteosarcoma patients. Functionally, 91H promotes the cellular proliferation, invasion and migration in both colorectal cancer and osteosarcoma. However, 91H is low-expressed in esophageal squamous cell carcinoma (ESCC) (4), with the higher depth of invasion, neoplastic grading and TNM. 91H expression is also associated with the density of demethylation agent, H19 ICR methylation. Moreover, it can inhibit IGF2 expression in ESCC patients.
|LncRNA||tissue||cancer type||expression level||oncogene/suppress gene||pathway||binding gene/factor||associated gene/factor||proliferation||apoptosis||migration||EMT||invasion||metastasis||prognosis||tag||PMID|
|1||91H||esophagus||esophageal squamous cell cancer||down||TS||IGF2-||epigenetic modification||24706416|
. Deng Q, He B, Gao T, Pan Y, Sun H, et al. (2014). Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer. PLoS One 9(7): e103022. link pubmed
. Berteaux N, Aptel N, Cathala G, Genton C, Coll J, et al. (2008). A novel H19 antisense RNA overexpressed in breast cancer contributes to paternal IGF2 expression. Mol Cell Biol 28(22): 6731-45. link pubmed
. Xia WK, Lin QF, Shen D, Liu ZL, Su J, et al. (2016). Clinical implication of long noncoding RNA 91H expression profile in osteosarcoma patients. Onco Targets Ther 9: 4645-52. link pubmed
. Gao T, He B, Pan Y, Xu Y, Li R, et al. (2015). Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression. Mol Carcinog 54(5): 359-67. link pubmed